Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Luye Pharma Group ( (HK:2186) ) has shared an announcement.
Luye Pharma Group Ltd. has announced that its board of directors will meet on August 28, 2025, to approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.13 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, focusing on the development, production, and sale of innovative medications. The company operates in the healthcare industry, providing a range of pharmaceutical products to meet various medical needs.
YTD Price Performance: 75.12%
Average Trading Volume: 111,824,541
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.33B
For detailed information about 2186 stock, go to TipRanks’ Stock Analysis page.